


Patients with newly diagnosed *FLT3*-mutated AML / MDS-EB2 (age ≥18 yrs)



patients ≥ 61 years of age will receive induction cycle 2 without daunorubicin

* depending on risk classification and study group

* Note: patients who have no signs of leukemia but do not formally fulfill the criteria of CR/CRi (morphologic leukemia free state (MLFS) according to ELN2017 definition) are also allowed to continue treatment on protocol.

@ patients ≥ 61 years of age will receive consolidation chemo option 1 with dose adjustment of mitoxantrone (days 1-3)

% patients ≥ 61 years of age will receive consolidation chemo option 1 with dose adjustment of etoposide (days 1-3)

& patients ≥ 61 years of age will receive consolidation chemo option 2 with dose adjustment of ara-C to 2000 mg/m²

\$ alternatively, patients in CR may proceed directly to maintenance treatment without receiving consolidation treatment

Quelle: https://hovon.nl/cache/public/ho156_flow_draft_16jun2018-1_c18xNjAweDBfZF8xX2dpZl8vX2Fzc2V0L19wcm12YXRIL3RyaWFsbWFuYUWdlci9zdGF0aWMM_23d498b2.gif